中国生物制药(01177) 自主研发的罗伐昔替尼片"TQ05105 (JAK/ROCK抑制剂)"被纳入突破性治疗药物程 序 复宏汉霖(02696)：HLX79注射液联合汉利康® 治疗活动期肾小球肾炎的2期临床研究于中国境内完成首 例患者给药 瑛泰医疗(01501)拟出资不超过1.1亿元参设怀格广泰基金 晋景新能(01783)建议股份拆细 【财报数据】 国泰航空(00293)发布中期业绩 股东应占溢利36.51亿港元 同比增长1.1% 中期息每股20港仙 【重大事项】 国泰航空(00293)购买十四架波音777-9型飞机 恒瑞医药(01276)：注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺 癌适应症获得美国 FDA孤儿药资格认定 百济神州(06160)发布第二季度业绩 净利润9432万美元 同比扭亏为盈 新鸿基公司(00086)发盈喜 预计中期股东应占溢利同比增加至不低于8亿港元 维信金科(02003)发盈喜，预期中期综合净利润不少于2亿元 同比大幅增长 赤子城科技(09911)发盈喜 预计中期股东应占利润同比增长约108.9%至126.7% 华显光电(00334)发盈喜 预期上半年 ...

【重大事项】 国泰航空(00293)购买十四架波音777-9型飞机 恒瑞医药(01276)：注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺 癌适应症获得美国 FDA孤儿药资格认定 中国生物制药(01177) 自主研发的罗伐昔替尼片"TQ05105 (JAK/ROCK抑制剂)"被纳入突破性治疗药物程 序 复宏汉霖(02696)：HLX79注射液联合汉利康® 治疗活动期肾小球肾炎的2期临床研究于中国境内完成首 例患者给药 瑛泰医疗(01501)拟出资不超过1.1亿元参设怀格广泰基金 国泰航空(00293)发布中期业绩 股东应占溢利36.51亿港元 同比增长1.1% 中期息每股20港仙 统一企业中国(00220)发布中期业绩，股东应占溢利12.87亿元，同比增加33.24% 百济神州(06160)发布第二季度业绩 净利润9432万美元 同比扭亏为盈 新鸿基公司(00086)发盈喜 预计中期股东应占溢利同比增加至不低于8亿港元 维信金科(02003)发盈喜，预期中期综合净利润不少于2亿元 同比大幅增长 赤子城科技(09911)发盈喜 预计中期股东应占利润同比增长约108.9%至126.7% ...

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for injection of Rukang Qutuzumab combined with Atezolizumab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weimeng Jin Ke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - Zhi Zi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics Technology (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

1）业绩速递 百济神州(06160.HK)：上半年营收175.18亿元，同比上升46%；产品收入为173.6亿元，同比上升45.8%；净利润4.5亿元，同比扭亏为盈。 统一企业中国(00220.HK)：上半年收入约为170.87亿元，同比上升10.6%；净利润约12.87亿元，同比上升33.2%。 赤子城科技(09911.HK)：发布盈喜，预计中期收入约31.35亿-32.15亿元，同比增约38.0%-41.5%；净利润约为4.7亿-5.1亿元。同比增长约108.9%-126.7%。 智通财经8月6日讯（编辑 冯轶 汤赞淇）智通财经为您带来今日港股重要公告 维信金科(02003.HK)：发布盈喜，预计中期净利润超2亿元，同比大幅增长。 翼辰实业(01596.HK)：发布盈喜，预计中期净利润约4870万元，同比扭亏为盈。 华显光电(00334.HK)：发布盈喜，预计中期净利润超4880万元，同比增超600%。 迈富时(02556.HK)：发布盈喜，预计中期净利润约3180万-4100万元，同比扭亏为盈。 心玮医疗-B(06609.HK)：发布盈喜，预计中期净利润超4000万元，同比扭亏为盈。 中国核能科技(00 ...

格隆汇8月6日丨复宏汉霖(02696.HK)发布公告，近日，一项HLX79注射液(人唾液酸酶融合蛋白) ("HLX79")联合汉利康®(利妥昔单抗注射液)("汉利康®")治疗活动期肾小球肾炎的2期临床研究于中国境 内(不包括中国港澳台地区)完成首例患者给药。 ...